Company Description
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1.
Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor.
The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
| Country | Cayman Islands |
| Founded | 2004 |
| IPO Date | Sep 29, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 127 |
| CEO | Yang Lu |
Contact Details
Address: 685 U.s. Highway One, 2nd Floor North Brunswick, New Jersey 08902 United States | |
| Phone | 848-230-7430 |
| Website | adlainortye.com |
Stock Details
| Ticker Symbol | ANL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $23.00 |
| CIK Code | 0001944552 |
| ISIN Number | US00704R1095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Yang Lu | Chief Executive Officer and Chairman |
| Wei Zhang | Chief Financial Officer |
| Dr. Kaiyang Tang | Senior Vice President and Global Head of Clinical Operations |
| Dr. Victoria Elizabeth Demby Ph.D. | Senior Vice President and Global Head of Regulatory Affairs |
| Dr. Ngai Chiu Tse M.D., Ph.D. | Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 13, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 19, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 2, 2024 | 6-K | Report of foreign issuer |
| Mar 4, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 15, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Feb 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Jan 31, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 13, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Sep 29, 2023 | 424B4 | Prospectus |